GlaxoSmithKline Pharmaceuticals logo

GlaxoSmithKline Pharmaceuticals

GLAXO NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹46,487 Cr
Volatility
Moderate
P/E Ratio
43.95
EBITDA
₹1,455 Cr
Return on Equity
45.69%
Debt to Equity
0.01
Book Value
₹133.85
EPS
₹45.47
52W High
₹3,120.7
52W Low
₹2,088.1

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
  • Company has been maintaining a healthy dividend payout of 94.6%

Weaknesses

2
  • Stock is trading at 20.7 times its book value
  • The company has delivered a poor sales growth of 5.49% over past five years.

Growth Rate

Revenue Growth
1.85% lower than 3Y
Net Income Growth
11.69% lower than 3Y
Cash Flow Change
-29.97% lower than 3Y
ROE
-3.89% lower than 3Y
ROCE
-3.3% lower than 3Y
EBITDA Margin (Avg.)
7.95% lower than 3Y

AI Analysis — Bull vs Bear

5d ago
AI opinion · based on fundamentals
Risk medium

GlaxoSmithKline Pharmaceuticals Ltd has a market capitalisation of about ₹47,983 Cr and trades at a P/E of 44.8x and a P/B of 21.11x. It is almost debt free, has kept ROE between 43% and 48% over the last 3 to 5 years, and pays out about 94.6% of profits as dividends, giving a 2.01% yield. Profit has grown 15% a year over 5 years, but sales have grown only about 5.49% a year over the same period, so most of the earnings growth has come from better margins rather than higher sales.

Bull Case 7
  • ROE has stayed high: 46% last year, 43% on a 3-year basis and 48% on a 5-year basis. That means the business earns a lot on the equity it uses.
  • The company is almost debt free, so its balance sheet carries little financial risk and it has room to handle downturns without borrowing.
  • Profit has grown faster than sales in every period: 18% vs 6% over 3 years, 15% vs 5% over 5 years and 11% vs 6% on a TTM basis. This points to steady margin expansion and cost control.
  • The dividend payout ratio of 94.6% and a dividend yield of 2.01% are high for a healthcare stock trading at 44.8x earnings, and they return a steady stream of cash to shareholders.
  • The stock has returned 23% a year over 3 years, which suggests the market has rewarded the recent improvement in profits.
  • 10-year ROE of 33% has risen to 43-48% over the last 3 to 5 years, showing that capital efficiency has improved over time.
  • Profit has grown 10% a year over 10 years even though sales grew only 3% a year. This suggests the business keeps improving profitability without needing much new capital.
Bear Case 7
  • The stock trades at 21.11x book value, which is a very high multiple and leaves little room for error if earnings disappoint.
  • At a P/E of 44.8x, the stock is priced well above its TTM profit growth of 11%. The valuation depends on the current level of profitability holding up.
  • Sales growth has been slow: 5.49% a year over 5 years, 6% over 3 years and only 3% a year over 10 years. That limits how much the business can grow without further margin gains.
  • Profit growth has slowed from 18% a year over 3 years to 11% on a TTM basis. The gains from margin expansion may be getting smaller.
  • Because 94.6% of profits are paid out as dividends, very little is kept back for reinvestment, acquisitions or building new capacity. This may hold back future sales growth.
  • The stock has returned only 5% over the past year and 7% a year over 10 years, which is modest for long-term holders.
  • ROE fell from 48% (5-year) to 43% (3-year). Very high ROE figures are partly the result of the high payout keeping the equity base small, so they may overstate how strongly the business can grow.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

21h ago
Neutral 2
  • Shareholders approve board appointments Sep 15

    Shareholders approved, by postal ballot, the appointment of Karine Natland as Non-Executive Director and the re-appointment of Bhushan Akshikar as Managing Director. Keeping Akshikar as MD means the same leader stays in charge.

  • Trading window shut before Q2FY27 Sep 25

    GSK Pharma closes its trading window from October 1, 2026, ahead of its Q2FY27 results. The window stays closed until 48 hours after the results are announced.

TL;DR: Recent news for GSK Pharma is limited to routine governance and compliance items, with no clear positives or headwinds. Shareholders backed the board appointments, and re-appointing MD Bhushan Akshikar keeps the current strategy in place. The two articles say nothing about operations, pricing, or demand, so the trend can't be judged from them. The next real test is the Q2FY27 results, expected in October 2026, which should show revenue growth, margins, and progress on the company's key brands.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
762
957
805
930
815
1,011
949
974
805
980
1,041
995
938
Expenses
618
668
587
673
584
689
658
641
554
644
670
644
643
Operating Profit
144
289
218
257
231
322
292
333
251
336
371
351
296
OPM %
19%
30%
27%
28%
28%
32%
31%
34%
31%
34%
36%
35%
31%
Other Income
54
28
-135
32
36
39
35
41
44
36
50
36
44
Interest
0
0
0
1
0
0
0
1
0
1
1
1
1
Depreciation
16
18
17
18
16
17
19
15
16
17
20
13
16
PBT
181
299
65
271
249
344
308
359
279
354
400
373
322
Tax %
27%
27%
30%
28%
27%
27%
25%
27%
27%
27%
26%
26%
26%
Net Profit
132
218
46
194
182
252
230
263
205
257
296
278
237
EPS in Rs
7.81
12.84
2.7
11.48
10.76
14.91
13.57
15.52
12.1
15.2
17.45
16.4
14
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,305
2,838
2,908
2,871
3,128
3,224
2,926
3,278
3,252
3,454
3,749
3,822
3,955
Expenses
2,672
2,360
2,489
2,363
2,527
2,567
2,327
2,516
2,447
2,545
2,570
2,512
2,601
Operating Profit
633
478
420
508
601
657
598
762
804
909
1,179
1,309
1,354
OPM %
19%
17%
14%
18%
19%
20%
20%
23%
25%
26%
31%
34%
34%
Other Income
149
125
119
70
131
-262
9
1,401
103
-21
149
166
166
Interest
0
0
0
0
1
6
4
2
2
2
1
3
3
Depreciation
25
25
27
38
49
83
79
68
66
70
67
66
67
PBT
756
578
511
540
683
306
525
2,093
839
816
1,260
1,406
1,449
Tax %
37%
35%
34%
35%
35%
70%
32%
19%
27%
28%
26%
26%
—
Net Profit
476
376
337
351
445
93
358
1,695
611
590
928
1,036
1,068
EPS in Rs
28.12
22.2
19.88
20.7
26.29
5.5
21.14
100
36.05
34.83
54.75
61.15
63.05
Div. Payout %
111%
113%
75%
85%
76%
727%
142%
90%
89%
92%
99%
93%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
85
85
85
85
169
169
169
169
169
169
169
169
Reserves
1,744
2,099
1,922
1,973
1,970
1,651
1,309
2,494
1,572
1,608
1,782
2,098
Borrowings
3
2
2
1
1
0
35
20
16
19
10
33
Other Liabilities
1,384
869
995
1,889
1,771
1,315
1,602
1,950
1,570
1,760
2,147
2,023
Total Liabilities
3,216
3,055
3,004
3,947
3,911
3,136
3,115
4,633
3,327
3,557
4,108
4,324
Fixed Assets
123
204
258
325
432
758
387
331
330
321
284
281
CWIP
115
268
605
923
1,003
120
13
30
20
14
14
33
Investments
0
6
0
0
0
0
0
366
518
813
1,118
1,392
Other Assets
2,977
2,577
2,140
2,700
2,477
2,257
2,715
3,907
2,458
2,408
2,692
2,618
Total Assets
3,216
3,055
3,004
3,947
3,911
3,136
3,115
4,633
3,327
3,557
4,108
4,324
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
338
139
234
473
409
490
578
811
484
582
1,290
903
Investing
180
499
301
-104
-153
-57
418
-406
808
9
-46
397
Financing
-497
-638
-511
-307
-358
-428
-696
-524
-1,543
-562
-769
-737
Net Cash Flow
21
0
24
62
-102
6
300
-119
-251
29
475
563
Free Cash Flow
175
-69
-24
639
166
336
536
2,371
451
573
1,273
870
CFO/OP
93
72
94
133
101
103
121
122
93
92
116
93
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
11
16
21
19
14
11
27
23
22
23
28
26
Inventory Days
91
156
111
147
131
135
159
144
131
144
126
124
Days Payable
74
97
73
149
109
100
135
156
122
171
186
154
Cash Conversion Cycle
27
75
60
17
36
46
50
11
31
-4
-31
-4
Working Capital Days
-48
26
7
-90
-72
-38
-39
-94
-57
-64
-99
-91
ROCE %
42%
29%
22%
26%
31%
33%
38%
37%
36%
51%
63%
61%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view GlaxoSmithKline Pharmaceuticals insights

66 extracted metrics + investor summaries across FY13–FY27.

Log in — free

Shareholding Pattern

Others2.20%Promot.75.00%FIIs4.79%DIIs7.80%Public10.21%As ofJun 2026

Documents

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals

What does Glaxosmithkline Pharmaceuticals Ltd do?
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Where is Glaxosmithkline Pharmaceuticals Ltd (GLAXO) listed?
Glaxosmithkline Pharmaceuticals Ltd trades as GLAXO on the NSE and under code 500660 on the BSE.
Which sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
Glaxosmithkline Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has a market capitalisation of ₹46,487 Cr, which places it in the Large Cap band.
What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd trades at a PE ratio of 43.95, on earnings per share of ₹45.47, against a book value of ₹133.85 per share.
What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd?
Over the last 52 weeks Glaxosmithkline Pharmaceuticals Ltd has traded between ₹2,088.1 and ₹3,120.7.
Does Glaxosmithkline Pharmaceuticals Ltd pay dividends?
Glaxosmithkline Pharmaceuticals Ltd has a dividend yield of 2.06%.
What is the Return on Equity (ROE) of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd reported a return on equity of 45.69%. Its debt-to-equity ratio is 0.01.

Company Information

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Website gsk-india.com
CEO Mr. Bhushan Akshikar
Employees 3,113
Listed 2000-12-15
Face Value ₹ 10
Issued Size 16,94,06,034

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GLAXO.md for Glaxosmithkline Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List